8-K: PetMed Express Changes Auditors Amid Control Weaknesses

PetMed Express, Inc. has appointed Baker Tilly US, LLP as its new independent registered public accounting firm, replacing RSM US LLP, following a competitive process and ongoing material weaknesses in internal controls.

Summary

• PetMed Express, Inc. has engaged Baker Tilly US, LLP as its new independent registered public accounting firm for the fiscal year ending March 31, 2026, following a competitive process.
• RSM US LLP was dismissed as the Company's independent registered public accounting firm, effective upon completion of its interim review of quarterly information for the three-month periods ended June 30, 2025, and September 30, 2025.
• RSM's reports on the Company's consolidated financial statements for the fiscal years ended March 31, 2025, and March 31, 2024, did not contain any adverse opinion or disclaimer, nor were they qualified or modified.
• No disagreements, as defined by Regulation S-K, existed between the Company and RSM on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure.
• However, significant reportable events were identified during RSM's tenure, including material weaknesses in internal controls over financial reporting.
• These weaknesses included issues with information technology general controls (ITGCs), errors in US GAAP application for sales tax liability, misapplication of Internal Revenue Code 162(m) regarding executive compensation, and a material error in PetCareRx purchase accounting related to deferred tax assets and goodwill valuation.
• These errors resulted in restatements of the Company's audited consolidated financial statements for the years ended March 31, 2023, 2022, and 2021, and various unaudited condensed consolidated quarterly financial statements.
• Additional material weaknesses were identified in October 2025, based on an Audit Committee investigation conducted from June to August 2025.
• These additional weaknesses related to an ineffective control environment, risk assessment process, information and communication process, and monitoring activities, specifically citing issues with 'tone at the top' and effectiveness of governance.
• Governance failures included a lack of commitment to the Code of Business Conduct and Ethics, ineffective whistleblower processes, inadequate communication of alleged Code of Conduct violations, and a lack of continuous risk assessment.
• The former Audit Committee chair did not promptly report whistleblower complaints to RSM US LLP.
• These governance issues contributed to material weaknesses in revenue recognition (AutoShip revenue recorded prematurely) and controls over cooperative advertising and vendor reimbursements, leading to further restatements for fiscal years ended March 31, 2024, and 2023, and interim periods.
• Errors in the calculation of the income tax provision and deficiencies in evaluating impairment for long-lived assets were identified in fiscal 2025 and corrected prior to the issuance of audited financials.
• The identified material weaknesses have not been fully remediated as of December 8, 2025.
• No consultations occurred between the Company and Baker Tilly regarding accounting principles, audit opinions, disagreements, or reportable events prior to their engagement.
• The Company does not anticipate the change in auditors will impact the timing of its first and second quarter fiscal 2026 Form 10-Q filings.

Sentiment

Score: 2

Explanation: The sentiment is highly negative due to the extensive list of un-remediated material weaknesses in internal controls, multiple financial restatements, and significant corporate governance failures, including issues with 'tone at the top' and whistleblower processes. These issues indicate severe deficiencies in financial reporting reliability and oversight.

Positives

• The Audit Committee conducted a competitive process to determine the independent registered public accounting firm, indicating a proactive approach to auditor selection.
• The Company has authorized RSM to respond fully to inquiries from Baker Tilly concerning the reportable events, facilitating a smooth transition and knowledge transfer.
• The Company does not anticipate the change in auditors will impact the timing of its Q1 and Q2 fiscal 2026 Form 10-Q filings, suggesting efforts to maintain reporting schedules.

Negatives

• Extensive and multiple material weaknesses in internal controls over financial reporting have been identified, including ITGCs, sales tax liability, executive compensation, and PetCareRx purchase accounting.
• These control weaknesses led to restatements of consolidated financial statements for fiscal years ended March 31, 2023, 2022, and 2021, and various interim periods.
• Additional material weaknesses were identified in October 2025, stemming from an Audit Committee investigation, highlighting fundamental failures in the control environment, risk assessment, information and communication, and monitoring activities.
• Significant corporate governance failures were noted, including a lack of 'tone at the top,' ineffective whistleblower processes, inadequate communication of Code of Conduct violations, and insufficient risk assessment.
• The former Audit Committee chair failed to promptly report whistleblower complaints to the external auditors.
• These governance issues contributed to further material weaknesses in revenue recognition (AutoShip revenue recorded prematurely) and controls over cooperative advertising and vendor reimbursements, leading to additional restatements for fiscal years ended March 31, 2024, and 2023, and interim periods.
• Errors in income tax provision calculation and impairment evaluation for long-lived assets were identified in fiscal 2025.
• The identified material weaknesses have not been fully remediated as of December 8, 2025, indicating ongoing significant control deficiencies.

Risks

• Ongoing material weaknesses in internal controls over financial reporting pose a high risk of future financial misstatements and restatements.
• Ineffective 'tone at the top' and governance failures increase the risk of non-compliance with ethical standards, potential fraud (including management override of controls), and regulatory scrutiny.
• Deficiencies in the whistleblower process and communication of Code of Conduct violations create a risk of undetected misconduct and a lack of accountability.
• Lack of an effective and continuous risk assessment process means the Company may not properly identify and analyze risks, including those related to financial misstatement.
• The need for multiple restatements and identified errors in various financial areas (sales tax, executive compensation, purchase accounting, revenue recognition, income tax) indicates a systemic issue with financial reporting reliability.
• Failure to fully remediate material weaknesses could lead to adverse opinions on internal controls in future audit reports, impacting investor confidence and potentially stock price.
• Potential for increased regulatory oversight and enforcement actions by the SEC due to persistent control deficiencies and restatements.

Future Outlook

The Company does not anticipate that the change in its independent registered public accounting firm will impact the timing of the filing of its first and second quarter fiscal 2026 Form 10-Qs. Remediation of the described material weaknesses is ongoing.

Management Comments

• The Company intends to file an amendment to this Current Report on Form 8-K with the specific date of dismissal of RSM US LLP and an update to the disclosures required by Item 304(a) of Regulation S-K.
• The Company does not anticipate that the change in its independent registered public accounting firm beginning with the fiscal 2026 third quarter will impact the timing of the filing of the first and second quarter fiscal 2026 Form 10-Qs.

Industry Context

This announcement is primarily company-specific, highlighting significant internal control and governance issues. While all public companies are expected to maintain robust internal controls, the extent and persistence of the identified material weaknesses at PetMed Express, Inc. are concerning and place it significantly below best practices for financial reporting within the broader industry.

Comparison to Industry Standards

• The presence of multiple, un-remediated material weaknesses in internal controls over financial reporting, leading to numerous restatements, falls significantly below industry standards for financial reporting integrity and corporate governance.
• Companies like Chewy, Inc. (CHWY) or Petco Health and Wellness Company, Inc. (WOOF), while operating in the same sector, generally demonstrate more robust internal control environments and fewer instances of significant financial restatements or auditor disagreements.
• The identified 'tone at the top' issues and failures in whistleblower processes are critical governance deficiencies that would be considered unacceptable compared to leading practices among well-governed public companies.
• The need for restatements across multiple fiscal years and interim periods due to errors in GAAP application, tax provisions, and acquisition accounting indicates a level of control breakdown not typically seen in financially healthy, well-managed industry peers.

Stakeholder Impact

• Shareholders face increased risk due to unreliable financial reporting, potential for further restatements, and uncertainty regarding the effectiveness of internal controls, which could negatively impact share price.
• Employees may be affected by a corporate culture where 'tone at the top' is weak and whistleblower processes are ineffective, potentially impacting morale and trust.
• Regulatory bodies, particularly the SEC, are likely to maintain heightened scrutiny over the Company's financial reporting and internal control remediation efforts.
• The change in auditors and the underlying control issues could impact the Company's reputation and relationships with suppliers and creditors, potentially affecting terms of business or credit.

Next Steps

• The Company intends to file an amendment to this Current Report on Form 8-K with the specific date of RSM's dismissal.
• The Company will continue its efforts to remediate the identified material weaknesses in internal controls over financial reporting.

Key Dates

Recommendation

A 'strong sell' recommendation is warranted due to the severe and un-remediated material weaknesses in internal controls over financial reporting, which have led to multiple restatements across several fiscal years. The identified corporate governance failures, including a weak 'tone at the top' and ineffective whistleblower processes, indicate systemic issues that undermine the reliability of financial statements and increase operational and regulatory risks. The lack of full remediation suggests these problems are ongoing and could lead to further financial instability and erosion of investor confidence. Until these fundamental issues are demonstrably resolved, the investment risk is exceptionally high.

Keywords

PetMed Express, PETS, auditor change, independent registered public accounting firm, internal controls, material weaknesses, financial reporting, SEC filing, corporate governance, restatement, Baker Tilly, RSM US, Audit Committee, whistleblower, risk management